AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment feasibility as perceived by patients
Number of subjects: 0
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment feasibility as perceived by relatives
Number of subjects: 0
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by physicians
Number of subjects: 0
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by nurses
Number of subjects: 0
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by patients
Number of subjects: 0
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by relatives
Number of subjects: 0
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for inpatient management
Number of subjects: 0
Study 20222964 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions across LRTI subgroups
Number of subjects: 0
Study 18038273 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 120
Study 18038273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16152821 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingxin Capsule (QC)
Number of subjects: 206
Study 16152821 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 206
Study 16152821 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 206
Study 16152821 — intervention group
Group type: EXPERIMENTAL
Intervention: AT1R AC plus CC gene type in EH patients
Number of subjects: 206
Study 16152821 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele distribution
Number of subjects: 206
Study 16152821 — intervention group
Group type: EXPERIMENTAL
Intervention: AA gene type vs AA plus CC gene type
Number of subjects: 206
Study 16152821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene type and TCM syndrome type
Number of subjects: 206
Study 16152821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene type and hypotensive effect of treatments
Number of subjects: 206
Study 12505568 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 374
Study 12505568 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 80 mg
Number of subjects: 374
Study 12505568 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 374
Study 12505568 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 80 mg
Number of subjects: 374
Study 12505568 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 374
Study 11008854 — intervention group
Group type: EXPERIMENTAL
Intervention: Two treatments focused on improving interpersonal relationships with social skills training
Number of subjects: 68
Study 11008854 — intervention group
Group type: EXPERIMENTAL
Intervention: Two treatments focused on improving interpersonal relationships without social skills training
Number of subjects: 68
Study 11008854 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 68
Study 8880291 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg twice a day for 5 days)
Number of subjects: 12
Study 8880291 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once a day for 3 days)
Number of subjects: 12
Study 8880291 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 12
Study 2050329 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (10 mg/day)
Number of subjects: 0
Study 2050329 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (25 mg/day)
Number of subjects: 0
Study 2050329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 6630285 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin only (60 mg/m2)
Number of subjects: 12
Study 6630285 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2) with tocopherol (200 mg i.m. 6 h before treatment) and nifedipine (60 mg p.o. daily from 2 days before infusion)
Number of subjects: 12
Study 6630285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tocopherol and nifedipine pretreatment
Number of subjects: 12
Study 31805483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing NaF 22,500 ppm
Number of subjects: 50
Study 31805483 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing NaF 900 ppm and casein phosphopeptide-amorphous calcium phosphate fluoride (CPP-ACPF)
Number of subjects: 50
Study 31805483 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitising cream containing NaF 9,000 ppm associated with 20% nanohydroxyapatite
Number of subjects: 50
Study 31805483 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with NaF 5,000 ppm associated to tricalcium phosphate
Number of subjects: 50
Study 31805483 — intervention group
Group type: COMPARATOR
Intervention: Milli-Q water (Control)
Number of subjects: 50
Study 30658483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (3200 IU daily for 3 months)
Number of subjects: 40
Study 30658483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 3 months)
Number of subjects: 40
Study 29308517 — intervention group
Group type: EXPERIMENTAL
Intervention: Raypex5 group
Number of subjects: 90
Study 29308517 — intervention group
Group type: EXPERIMENTAL
Intervention: i-root group
Number of subjects: 90
Study 29308517 — intervention group
Group type: COMPARATOR
Intervention: X-ray group
Number of subjects: 90
Study 29308517 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar teeth
Number of subjects: 90
Study 29308517 — intervention group
Group type: EXPERIMENTAL
Intervention: Premolar teeth
Number of subjects: 90
Study 29308517 — intervention group
Group type: EXPERIMENTAL
Intervention: Front teeth
Number of subjects: 90
Study 25733459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast (35% protein/45% carbohydrate)
Number of subjects: 12
Study 25733459 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate breakfast (15% protein/65% carbohydrate)
Number of subjects: 12
Study 24152185 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 407
Study 24152185 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine plus gabapentin
Number of subjects: 407
Study 24152185 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 407
Study 23091134 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% contaminated corn
Number of subjects: 1200
Study 23091134 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% contaminated corn
Number of subjects: 1200
Study 23091134 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated corn (increased percentage)
Number of subjects: 1200
Study 23091134 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 50% contaminated corn
Number of subjects: 1200
Study 23091134 — intervention group
Group type: EXPERIMENTAL
Intervention: AFB(1) and AFB(2) contaminated groups
Number of subjects: 1200
Study 23091134 — intervention group
Group type: EXPERIMENTAL
Intervention: Contaminated corn (increased concentration)
Number of subjects: 1200
Study 19650424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosed submaximal physical exercise
Number of subjects: 61
Study 19650424 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosed maximal physical exercise
Number of subjects: 61
Study 19650424 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal physical activity)
Number of subjects: 61
Study 17391816 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml dose of 7-valent pneumococcal conjugate vaccine
Number of subjects: 220
Study 17391816 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml dose of 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 220
Study 15379756 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (26 weeks; combined strength and endurance exercises, four sessions/week: two supervised and two at home)
Number of subjects: 29
Study 15379756 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 29
Study 15379756 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (26 weeks)
Number of subjects: 29
Study 11255811 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms dry misoprostol
Number of subjects: 430
Study 11255811 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms wet misoprostol
Number of subjects: 430
Study 11255811 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms wet misoprostol
Number of subjects: 430
Study 10220541 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker treatment
Number of subjects: 0
Study 10220541 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker treatment in high risk patients requiring diuretics
Number of subjects: 0
Study 8907622 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloraminophene capsules
Number of subjects: 12
Study 8907622 — intervention group
Group type: COMPARATOR
Intervention: Chloraminophene tablets
Number of subjects: 12
Study 2528718 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-practice group (100 trials from four different practice locations)
Number of subjects: 23
Study 2528718 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific-practice group (100 trials from the test-target location)
Number of subjects: 23
Study 2528718 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated kicking activity)
Number of subjects: 23
Study 2528718 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-practice group
Number of subjects: 23
Study 2528718 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific-practice group
Number of subjects: 23
Study 2528718 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 941927 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular grades
Number of subjects: 0
Study 941927 — intervention group
Group type: COMPARATOR
Intervention: Special classes
Number of subjects: 0
Study 30176835 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) as add-on to antidepressant treatment
Number of subjects: 0
Study 30176835 — intervention group
Group type: COMPARATOR
Intervention: Placebo as add-on to antidepressant treatment
Number of subjects: 0
Study 27012420 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d all rac-α-tocopheryl acetate)
Number of subjects: 312
Study 27012420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin E and selenium (200 µg/d L-selenomethionine)
Number of subjects: 312
Study 27012420 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium alone (200 µg/d L-selenomethionine)
Number of subjects: 312
Study 27012420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 24938627 — intervention group
Group type: EXPERIMENTAL
Intervention: AF symptom severity (measured by Toronto AF Severity Scale)
Number of subjects: 558
Study 22023436 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (12-week duration)
Number of subjects: 38
Study 20398269 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate injections
Number of subjects: 120
Study 20398269 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 120
Study 18548482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 42
Study 18548482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15920042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 11-20 (17.1 +/- 0.4 METs per hour per week)
Number of subjects: 179
Study 15920042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 21-30 (27.0 +/- 0.5 METs per hour per week)
Number of subjects: 179
Study 15920042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 31-40 (37.5 +/- 0.5 METs per hour per week)
Number of subjects: 179
Study 15920042 — intervention group
Group type: EXPERIMENTAL
Intervention: Group >40 (58.3 +/- 1.8 METs per hour per week)
Number of subjects: 179
Study 15920042 — intervention group
Group type: COMPARATOR
Intervention: Group 0 (no activity)
Number of subjects: 179
Study 15920042 — intervention group
Group type: COMPARATOR
Intervention: Group 1-10 (6.8 +/- 0.3 METs per hour per week)
Number of subjects: 179
Study 11195741 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium surgery
Number of subjects: 27
Study 9771495 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression scale (HAD) at cut-off of 9/10
Number of subjects: 136
Study 9771495 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS mental health scale at cut-off score of 67/68
Number of subjects: 136
Study 7530883 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott TestPack Strep A Plus
Number of subjects: 1389
Study 7530883 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Strep A
Number of subjects: 1389
Study 7530883 — intervention group
Group type: EXPERIMENTAL
Intervention: Kodak SureCell Strep A
Number of subjects: 1389
Study 3203706 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 12
Study 3203706 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant treatment with 10 mg benazepril and 40 mg furosemide
Number of subjects: 12
Study 3203706 — intervention group
Group type: COMPARATOR
Intervention: 10 mg benazepril
Number of subjects: 12
Study 2407810 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FUra) administered intravenously at a dose of 370 mg/m2/d for 5 days
Number of subjects: 79
Study 2407810 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FUra) plus high-dose continuous infusion leucovorin calcium (500 mg/m2/d)
Number of subjects: 79
Study 971163 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 8‐h retardations in time (Westerly flight)
Number of subjects: 16
Study 971163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepiprazole hydrochloride (therapeutic preparation)
Number of subjects: 16
Study 971163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no time zone changes)
Number of subjects: 16
Study 31929401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 96
Study 31929401 — intervention group
Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 96
Study 31479152 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 51
Study 31479152 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 51
Study 28647745 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline delivered via high aerosol output nebulizer
Number of subjects: 61
Study 28647745 — intervention group
Group type: COMPARATOR
Intervention: 3% hypertonic saline delivered via low aerosol output nebulizers (large or small particles)
Number of subjects: 61
Study 25826125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise training (HET; 15% O2, n=20)
Number of subjects: 40
Study 25826125 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise training (NET; 21% O2, n=20)
Number of subjects: 40
Study 23772330 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) with preservation of the maxillary sinus ostium
Number of subjects: 30
Study 23772330 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) with enlargement of the maxillary sinus ostium
Number of subjects: 30
Study 23772330 — intervention group
Group type: COMPARATOR
Intervention: Uncinectomy only
Number of subjects: 30
Study 23772330 — intervention group
Group type: COMPARATOR
Intervention: Middle meatal antrostomy
Number of subjects: 30
Study 21161651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystone® (2 tablets BID for 1 year)
Number of subjects: 10
Study 21161651 — intervention group
Group type: COMPARATOR
Intervention: Cystone® (12 weeks crossover study)
Number of subjects: 10
Study 21161651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystone® (1 year open label study)
Number of subjects: 10
Study 19209082 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 27
Study 19209082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 27
Study 19209082 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 27
Study 17597461 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg single dose as adjunct to quinine)
Number of subjects: 21
Study 17597461 — intervention group
Group type: COMPARATOR
Intervention: Quinine treatment alone
Number of subjects: 21
Study 15234038 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐125
Number of subjects: 148
Study 15234038 — intervention group
Group type: COMPARATOR
Intervention: Pd‐103
Number of subjects: 148
Study 15234038 — intervention group
Group type: EXPERIMENTAL
Intervention: R300
Number of subjects: 148
Study 15234038 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of perirectal seeds ≤2.0 mm from rectal wall
Number of subjects: 148
Study 15234038 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of perirectal seeds 2‐4 mm from rectal wall
Number of subjects: 148
Study 11435528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-HMB (3 g/d)
Number of subjects: 31
Study 11435528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9736848 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical information plus information about barriers to behavioral change (study group)
Number of subjects: 13
Study 9736848 — intervention group
Group type: COMPARATOR
Intervention: Clinical information only (control group)
Number of subjects: 13
Study 9736848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study and control groups (combined)
Number of subjects: 13
Study 7914306 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (Hib conjugate vaccine) given by separate injection according to an accelerated 2, 3, and 4 month schedule without a booster dose in the second year of life.
Number of subjects: 0
Study 7914306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis of PRP-T vaccine.
Number of subjects: 0
Study 7914306 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine (Hib conjugate vaccine) with follow-up until November 1, 1993.
Number of subjects: 0
Study 3056331 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively
Number of subjects: 25
Study 3056331 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP‐5) 50 mg subcutaneously two hours preoperatively and 48 hours postoperatively
Number of subjects: 25
Study 3056331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30723168 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) for 30 min/session for 10 days
Number of subjects: 33
Study 30723168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS)
Number of subjects: 33
Study 30723168 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 33
Study 30723168 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) and Control group
Number of subjects: 33
Study 27306255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 μg)
Number of subjects: 50
Study 27306255 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (5 ± 2 mg for 24 hours at 2 mL/h)
Number of subjects: 50
Study 25255724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) - intravenous infusion of 5000 IU/kg before anesthesia and at the start of surgery
Number of subjects: 40
Study 25255724 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control group)
Number of subjects: 40
Study 23545598 — intervention group
Group type: EXPERIMENTAL
Intervention: MA-I (intensive computer)
Number of subjects: 126
Study 23545598 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-I (aerobic)
Number of subjects: 126
Study 23545598 — intervention group
Group type: EXPERIMENTAL
Intervention: MA-I/EX-I, MA-I/EX-C, MA-C/EX-I, MA-C/EX-C (all groups)
Number of subjects: 126
Study 23545598 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical plus mental activity (combined intervention)
Number of subjects: 126
Study 22117989 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg orally three times daily) plus fenofibrate (200 mg orally once daily)
Number of subjects: 87
Study 22117989 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg orally three times daily) plus placebo
Number of subjects: 87
Study 20183462 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal treatment for acute hepatitis
Number of subjects: 0
Study 20183462 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16606971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2) administered on days 1, 4, 8, and 11 of a 3-week cycle
Number of subjects: 51
Study 16606971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 51
Study 15764103 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led classroom curriculum intervention
Number of subjects: 27
Study 15764103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 15764103 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention for regular riders
Number of subjects: 27
Study 11316640 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg twice daily
Number of subjects: 405
Study 11316640 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 36 microg four times daily
Number of subjects: 405
Study 11316640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 9137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Raynaud phenomenon (RP) diagnosis confirmed by clinical examination and nailfold capillary microscopy.
Number of subjects: 2626
Study 9137327 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and occupation-related factors.
Number of subjects: 2626